AJANTPHARM

Growth in domestic branded formulations

1. Strong recent financial performance Ajanta Pharma reported solid growth in its recent quarterly results with revenue growth of around 20% year-on-year. Net profit also increased in the high-teens percentage range, supported by better margins and strong domestic branded formulation sales. 2. Growth in domestic branded formulations The company continues to perform well in the Indian branded generics market, particularly in therapies such as cardiology, dermatology, ophthalmology and pain management. These segments remain the key drivers of profitability. 3. Expansion in international markets Ajanta Pharma is expanding its presence in Asia, Africa and Latin America, focusing on branded generics rather than pure commodity generics. The company has been strengthening distribution networks and increasing field staff in several emerging markets. 4. Partnership for diabetes / obesity drugs Ajanta Pharma entered a collaboration to market semaglutide-based products in multiple international markets. Semaglutide is used for type-2 diabetes and obesity treatment, which is a rapidly growing global therapy area. 5. Investment for acquisitions and expansion The company has indicated plans to allocate a large capital pool for acquisitions and brand purchases, focusing on specialty therapies like dermatology, gynecology, and nephrology. 6. Investor engagement and management interactions Management has recently participated in investor conferences and analyst meetings, discussing growth strategy, international expansion, and new product launches.